Innovative Eyewear price to book ratio LUCY
Market value divided by the book value of the company's net assets, since 2022.
- Today, Oct 23, 2026
- 1.1×
- 4-year median
- 0.9×
- Against its 4-year history
- 59th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 0.5× to 7.6×
- Peer median
- 1.6×
Innovative Eyewear's price to book ratio is 1.1× as of Oct 23, 2026.
That is above its 4-year median of 0.9×, close to the middle of its last 4 years.
Over that time it ranged from 0.5× in May 2024 to 7.6× in Apr 2023.
The median for 5 healthcare stocks of a similar size is 1.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.1× | 0.5× | 1.2× |
| 2025 | 0.6× | 0.5× | 1.5× |
| 2024 | 1.1× | 0.5× | 4.4× |
| 2023 | 0.7× | 0.6× | 7.6× |
| 2022 | 1.8× | 1.0× | 1.8× |
Against its peers
Companies in Healthcare nearest Innovative Eyewear's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| LUCYInnovative Eyewear | 1.1× |
| NEPHNephros | 3.2× |
| ATNMActinium Pharmaceuticals | 1.6× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| Peer median | 1.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Innovative Eyewear
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.